SCHEMBL339297

SCHEMBL339297

COCCN(C)c1cnc2cc(CNC(=O)OC(C)(C)C)c(Br)cn12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SUV39H2 Q9H5I1 4/20 0.36
RECQL P46063 1/20 0.34
CKS1B P61024 1/20 0.33
SKP1 P63208 1/20 0.33
SKP2 Q13309 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
KDM4E B2RXH2 1/20 0.32
LMNA P02545 1/20 0.32
BRD4 O60885 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
METTL3 Q86U44 1/20 0.32
CA12 O43570 2/20 0.32
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
CA9 Q16790 2/20 0.32
PIK3CD O00329 1/20 0.31
NAMPT P43490 1/20 0.31
GFER P55789 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL338299 0.75 PIK3CD (0.38) SUV39H2HDAC10HDAC6KDM4ELMNA
SCHEMBL339442 0.73 NAMPT (0.40) SUV39H2HDAC10HDAC6KDM4ELMNA
SCHEMBL19794769 0.68 KDM4A (0.40) HDAC10HDAC6KDM4ELMNAL3MBTL1
SCHEMBL29639462 0.68 KDM4A (0.40) HDAC10HDAC6KDM4ELMNAL3MBTL1
SCHEMBL20157285 0.66 HDAC10 (0.40) SUV39H2HDAC10HDAC6KDM4ELMNA
SCHEMBL337994 0.66 KDM4A (0.39) KDM4ELMNAL3MBTL1CA12CA1
SCHEMBL12480621 0.66 CFD (0.44) SUV39H2HDAC10HDAC6CA12CA1
SCHEMBL338256 0.65 IDO1 (0.40) SUV39H2HDAC10HDAC6KDM4ELMNA
SCHEMBL16785098 0.65 BRD4 (0.44) CKS1BSKP1SKP2BRD4L3MBTL1
SCHEMBL29664291 0.65 CACNA1H (0.42) KDM4ELMNAL3MBTL1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077787-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2012-03-29 US disclosed
US-20120077787-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2012-03-29 US disclosed
US-8097617-B2 Organic compounds NOVARTIS AG (CH) 2012-01-17 US disclosed
US-8097617-B2 Organic compounds NOVARTIS AG (CH) 2012-01-17 US disclosed
US-8097617-B2 Organic compounds NOVARTIS AG (CH) 2012-01-17 US disclosed
US-20090253689-A1 Organic Compounds NOVARTIS AG (CH) 2009-10-08 US disclosed
US-20090253689-A1 Organic Compounds NOVARTIS AG (CH) 2009-10-08 US disclosed
US-20090253689-A1 Organic Compounds NOVARTIS AG (CH) 2009-10-08 US disclosed
EP-2004643-A1 ORGANIC COMPOUNDS Novartis AG (CH) 2008-12-24 EP disclosed
WO-2007113226-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2007-10-11 WO disclosed
WO-2007113226-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077787-A1 ORGANIC COMPOUNDS OAT, GPR119, OTC SUV39H2 3686/4885RECQL 3068/4885CKS1B 4068/4885
US-20090253689-A1 Organic Compounds OAT, GPR119, OTC SUV39H2 3686/4885RECQL 3068/4885CKS1B 4068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.